

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Oshlack et al.	Confirmation No.:	2376
Serial No.:	10/690,389	Art Unit:	1616
Filed:	October 21, 2003	Examiner:	Frank I. Choi
For:	MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS	Attorney Docket No.:	6750-362-999
		CAM No.:	305158-999362

AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the non-final Office Action dated June 3, 2008, please enter the following amendments and remarks in the above-identified application. Submitted herewith are: (1) a Petition for Extension of Time for two months from September 3, 2008 to and including November 3, 2008; (2) Exhibit A; (3) an Amendment Fee Transmittal; (4) a Supplemental Information Disclosure Statement and the accompanying List of References Cited By Applicant; and (5) reference D09.

No additional fee is believed to be due in connection with the filing of this Amendment. Should any fee be required, please charge such fee to Jones Day Deposit Account No. 50-3013.

A Listing of Claims begins on page 2.

Remarks begin on page 10.